Correction and Retraction: Treatment.com International Inc. (CSE: TRUE) Announces Strategic Partnership, Leadership Appointment, and Major Healthcare Contract to Drive AI Innovation in Healthcare

TheBullreport.com wishes to retract certain statements contained in an article issued on May 30, 2024, entitled “Treatment.com International Inc. Announces Strategic Partnership, Leadership Appointment, and Major Healthcare Contract to Drive AI Innovation in Healthcare.”

The article incorrectly stated that a new Chief Executive Officer has been appointed to Treatment.com AI as of May 15, 2024. This information is incorrect and Treatment.com AI has not appointed a new Chief Executive or any other management position. This reporting error originated from a third-party service hired to draft the article. Treatment.com AI neither reviewed nor approved of the article and was not aware of the contents. The document was erroneously released without the prior consent and approval of Treatment.com AI.

We apologize for any confusion this may have caused and confirm that Dr. Essam Hamza is the Chief Executive Officer and board member of Treatment.com AI now and since October 2023.

TheBullreport.com is committed to providing accurate and timely information to the public. We regret this oversight and are taking steps to ensure that all future communications undergo a rigorous review process by all relevant parties before dissemination.

Disclaimer: This news article is for information purposes only and is neither a solicitation or recommendation to buy nor an offer to sell securities. The Bull Report is not-a-registered-investment-advisor. The Bull Report is not a broker-dealer. Information, opinions, and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. The Bull Report accepts no liability for any losses arising from an investor’s reliance on the use of this material. Starting on Mar 15, 2024 The Bull Report has been compensated $47,000 per month for coverage of TRUE by third party. The Bull Report and its affiliates or officers may purchase, hold, and sell shares of common stock of this stock, in the open market at any time without notice. The Bull Report will not update its purchases and sales of this stock in any future postings on The Bull Report’s websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words “may”, “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend,” ” project,” and similar expressions and variations thereof are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *The Bull Report does not set price targets on securities. Never invest in a stock discussed on this website or in this email alert unless you can afford to lose your entire investment.

Media Contact
Company Name: TheBullReport
Contact Person: Jason Roy
Email: info@thebullreport.com
City: Dallas
State: Texas
Country: United States
Website: https://www.thebullreport.com/